BRUSSELS, July 01, 2026 (GLOBE NEWSWIRE) — SERB Pharmaceuticals, a global specialty pharmaceutical company designed to address rare and urgent conditions, today announced that it has completed the acquisition of exclusive development and commercialization rights to Idefirix® (imlifidase) in the European Union, United Kingdom, Switzerland, Norway, Liechtenstein, Iceland and the Middle East and North Africa (MENA) region from Hansa Biopharma. “Adding Idefirix to the SERB portfolio reflects SERB’s continued commitment to supplying medicines for rare and urgent conditions, where time and complexity leave no room for failure,” said Jeremie Urbain, Chairman of SERB Pharmaceuticals. “With SERB’s established commercial and medical capabilities and broad international footprint, we are well positioned to expand the availability of Idefirix®...

Acquisition brings core AI infrastructure fully in-house, strengthening Beeline’s ability to automate and scale across its product suite PROVIDENCE, R.I., July 01, 2026 (GLOBE NEWSWIRE) — via IBN — Beeline Holdings, Inc. (NASDAQ: BLNE) (“Beeline” or the “Company”), a technology-driven mortgage and title platform, today announced the completion of its acquisition of MagicBlocks, the artificial intelligence company whose technology powers Bob, Beeline’s proprietary AI agent, and underpins key automation capabilities across the Company’s mortgage origination and title operations. The acquisition gives Beeline full ownership and control of the AI technology already embedded across its platform. With MagicBlocks’ capabilities fully integrated, the Company expects to accelerate deployment of...

LAS VEGAS, July 01, 2026 (GLOBE NEWSWIRE) — Asia Broadband Inc. (OTC: AABB) (“AABB” or the “Company”) announces today that the Company has entered into a Letter of Intent (“LOI”) to acquire a high-grade gold and silver underground mining concession located in the Etzatlán region of Jalisco, Mexico, for a total consideration of $5,500,000 USD. The targeted mining concession is an underground mine mining property located in close proximity to the Company’s Etzatlán gold and silver processing plant. Based on historical drilling data analyzed to date by the Company, the property has advanced historical drilling results with highlights between 9 GPT (Grams Per Ton) and 12 GPT of gold, and between 350 GPT and 400 GPT of silver. The proposed acquisition is a strategic step forward in the Company’s...

GRAND RAPIDS, Mich., and HASTINGS, Mich., July 01, 2026 (GLOBE NEWSWIRE) — Independent Bank Corporation (NASDAQ: IBCP), the parent company of Independent Bank, with total assets of approximately $5.6 billion, today announced that it has completed its previously announced acquisition of HCB Financial Corp., the parent company of Highpoint Community Bank, with total assets of approximately $597 million, which has merged with and into Independent Bank Corporation. “We are excited to welcome Highpoint Community Bank’s customers, employees and shareholders to Independent Bank,” commented Brad Kessel, President and Chief Executive Officer of Independent Bank Corporation. “This merger strengthens our presence by bridging a geographic gap between Independent’s primary hubs in Grand Rapids and Lansing while supporting our planned growth...

PARIS, July 01, 2026 (GLOBE NEWSWIRE) — newcleo (or the “Company”), a pioneer in advanced modular reactor (“AMR”) technology and nuclear fuel manufacturing, today announced it has entered into an agreement to acquire Bonifait Pesage, a French manufacturer of nuclear-grade scales and precision industrial weighing equipment with a strong customer base in the French nuclear ecosystem. The acquisition forms part of newcleo’s vertical integration strategy, pursued since 2023 through the acquisitions of the EPCM and manufacturing companies Fucina, SRS and Rütschi. It will bring critical manufacturing capabilities in-house, secure preferred access to the nuclear-grade weighing equipment required for newcleo’s planned MOX fuel manufacturing facilities, reduce supply-chain risk and support equipment customization. Precision...

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree ANIMALCARE GROUP PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position...

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree ADVANCED MEDICAL SOLUTIONS GROUP PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date...

EUROBIO SCIENTIFIC FINALIZES THE ACQUISITION OF CAREDX’s TRANSPLANT LAB PRODUCT DIVISIONAcceleration of Eurobio’s strategic plan to become an in-vitro molecular diagnostics (“IVD”) leader Creation of a global leading provider of kits for genomic typing and transplantation diagnostics Acquisition of a 100% proprietary products portfolio Deeper capabilities and larger scale with technological and commercial complementaritiesParis, July 1st, 2026 ,8 AM CET Eurobio Scientific (FR0013240934, ALERS, PEA-PME eligible), a leading French group in in-vitro diagnostics for transplantation, oncology and infectious diseases, today announces that it has closed the acquisition of CareDx AB in Sweden and its fully owned subsidiaries in the United States and Australia that constitutes the Lab Products division of CareDx, Inc., a US global precision...

DEKUPLE Group continues its European growth with a majority stake acquisition in subko&co in Poland Paris, July 1st, 2026 (8:00 a.m.) – DEKUPLE Group, a European leader in communication and data marketing, announces the acquisition of a majority stake in subko&co, a Polish agency combining performance marketing, programmatic campaigns, data analytics and content creation for digital campaigns and MarTech solutions). Founded in 2013 by Marta Subko, a graduate of Sciences Po Paris, subko&co supports companies in their digital transformation and communication strategies. The agency has notably distinguished itself through its ability to build bridges between the Polish and French-speaking markets, serving both local and international clients. Based in Warsaw, subko&co has developed recognized expertise in delivering digital...

Acquisition focused on clinical-stage program potravitug, a first-in-class BK polyomavirus monoclonal antibody Totality of evidence from the Phase II SAFE KIDNEY II trial supports initiation of pivotal Phase II/III trial later this year Ipsen expands rare disease portfolio to include serious and frequent post-transplant infection with no targeted approved treatmentsPARIS, FRANCE AND SCHLIEREN/ZURICH, SWITZERLAND, 01 JULY 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) and Memo Therapeutics AG announced today they have entered into a definitive share purchase agreement under which Ipsen has agreed to acquire all issued and outstanding shares of Memo Therapeutics AG. The anticipated acquisition is focused on potravitug, which is a Phase II clinical-stage antibody against the BK polyomavirus (BKPyV). BK polyomavirus associated nephropathy...